The Swedish specialty pharmaceutical company Pharmalink announced the appointment of Thomas Eklund as Chairman of the board.
Thomas Eklund joined the board on August 15, 2017.
Bengt Julander, Founder and outgoing Chairman of Pharmalink, said: "We are very happy to have Thomas on board as we prepare for taking our lead candidate drug Nefecon through a clinical Phase 3 study for patients with primary IgA nephropathy.
"Thomas’s broad knowledge and long experience from both the healthcare industry and the financial sector will be a welcome addition to the team."
Thomas has extensive experience from the pharmaceutical industry, medtech industry and the financial sector where he has held different leading positions, including CEO and Head of Europe at Investor Growth Capital.
Other previous positions include Investment Director at Alfred Berg ABN AMRO Capital Investment and VP at Handelsbanken Markets. He is currently Chairman of the board of Moberg Pharma and Itrim, and board member of Boule Diagnostics, Biotage, Neoventa Medical, Memira and Rodebjer Form.